Literature DB >> 23412609

Morbidity and mortality in type B Niemann-Pick disease.

Margaret M McGovern1, Natalie Lippa, Emilia Bagiella, Edward H Schuchman, Robert J Desnick, Melissa P Wasserstein.   

Abstract

PURPOSE: The purpose of this study was to perform a systematic evaluation of morbidity and mortality in type B Niemann-Pick disease.
METHODS: A total of 103 patients with Niemann-Pick disease (49 males, 54 females, age range: 1-72 years) participated in natural history studies through Mount Sinai's International Center for Types A and B Niemann-Pick Disease between 1992 and 2012.
RESULTS: Serious morbidities included significant neurological, hepatic, and cardiac disease. Thirteen patients had some degree of neurological impairment. Nine patients had cirrhosis or liver failure requiring transplantation. Coronary artery and valvular heart disease were present in nine patients. Of note, only four patients were oxygen dependent, although progressive pulmonary disease is a well-described feature of Niemann-Pick disease. During the follow-up period, 18 deaths occurred. The median age of death was 15.5 years (range 1-72). Causes of death included pneumonia, liver failure, and hemorrhage. The majority of deaths (12 of 18) occurred in patients <21 years, yielding a mortality rate of 19% in the pediatric population.
CONCLUSION: This study demonstrates that Niemann-Pick disease is a life-threatening disorder with significant morbidity and mortality, especially in the pediatric population. The information collected in this series highlights the need for safe, effective therapy for Niemann-Pick disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23412609     DOI: 10.1038/gim.2013.4

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  36 in total

1.  Successful within-patient dose escalation of olipudase alfa in acid sphingomyelinase deficiency.

Authors:  Melissa P Wasserstein; Simon A Jones; Handrean Soran; George A Diaz; Natalie Lippa; Beth L Thurberg; Kerry Culm-Merdek; Elias Shamiyeh; Haig Inguilizian; Gerald F Cox; Ana Cristina Puga
Journal:  Mol Genet Metab       Date:  2015-05-30       Impact factor: 4.797

2.  Solving the secretory acid sphingomyelinase puzzle: Insights from lysosome-mediated parasite invasion and plasma membrane repair.

Authors:  Norma W Andrews
Journal:  Cell Microbiol       Date:  2019-06-10       Impact factor: 3.715

3.  Epidemiological, clinical and biochemical characterization of the p.(Ala359Asp) SMPD1 variant causing Niemann-Pick disease type B.

Authors:  Mariana Acuña; Pablo Martínez; Carol Moraga; Xingxuan He; Mauricio Moraga; Bessie Hunter; Peter Nuernberg; Rodrigo A Gutiérrez; Mauricio González; Edward H Schuchman; José Luis Santos; Juan Francisco Miquel; Paulina Mabe; Silvana Zanlungo
Journal:  Eur J Hum Genet       Date:  2015-04-29       Impact factor: 4.246

4.  Cirrhosis and liver failure: expanding phenotype of Acid sphingomyelinase-deficient niemann-pick disease in adulthood.

Authors:  Olivier Lidove; Frédéric Sedel; Frédéric Charlotte; Roseline Froissart; Marie T Vanier
Journal:  JIMD Rep       Date:  2014-04-10

Review 5.  Types A and B Niemann-Pick disease.

Authors:  Edward H Schuchman; Robert J Desnick
Journal:  Mol Genet Metab       Date:  2016-12-16       Impact factor: 4.797

6.  Enhanced Delivery and Effects of Acid Sphingomyelinase by ICAM-1-Targeted Nanocarriers in Type B Niemann-Pick Disease Mice.

Authors:  Carmen Garnacho; Rajwinder Dhami; Melani Solomon; Edward H Schuchman; Silvia Muro
Journal:  Mol Ther       Date:  2017-06-09       Impact factor: 11.454

7.  Determination of 7-ketocholesterol in plasma by LC-MS for rapid diagnosis of acid SMase-deficient Niemann-Pick disease.

Authors:  Na Lin; Huiwen Zhang; Wenjuan Qiu; Jun Ye; Lianshu Han; Yu Wang; Xuefan Gu
Journal:  J Lipid Res       Date:  2013-11-04       Impact factor: 5.922

8.  Burden of Illness in Acid Sphingomyelinase Deficiency: A Retrospective Chart Review of 100 Patients.

Authors:  Gerald F Cox; Lorne A Clarke; Roberto Giugliani; Margaret M McGovern
Journal:  JIMD Rep       Date:  2018-07-12

9.  Control of CD1d-restricted antigen presentation and inflammation by sphingomyelin.

Authors:  Espen Melum; Xiaojun Jiang; Kristi D Baker; M Fatima Macedo; Jürgen Fritsch; C Marie Dowds; Jing Wang; Anne Pharo; Arthur Kaser; Corey Tan; Catia S Pereira; Samuel L Kelly; Jingjing Duan; Tom H Karlsen; Mark A Exley; Stefan Schütze; Dirk M Zajonc; Alfred H Merrill; Edward H Schuchman; Sebastian Zeissig; Richard S Blumberg
Journal:  Nat Immunol       Date:  2019-10-21       Impact factor: 25.606

10.  Novel first-dose adverse drug reactions during a phase I trial of olipudase alfa (recombinant human acid sphingomyelinase) in adults with Niemann-Pick disease type B (acid sphingomyelinase deficiency).

Authors:  Margaret M McGovern; Melissa P Wasserstein; Brian Kirmse; W Lane Duvall; Thomas Schiano; Beth L Thurberg; Susan Richards; Gerald F Cox
Journal:  Genet Med       Date:  2015-04-02       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.